AFT Pharmaceuticals partners with Mark Cuban Cost Plus Drug Company to distribute its non-opioid pain relief medication, COMBOGESIC, across the United States.
AFT Pharmaceuticals has secured a strategic distribution partnership with the Mark Cuban Cost Plus Drug Company to list its non-opioid pain relief medication, COMBOGESIC, on the Cost Plus Marketplace. This expansion into the US market provides a significant new channel for patient access, potentially driving volume growth for the product as it targets the mild to moderate acute pain segment.
COMBOGESIC, a combination of acetaminophen 325 mg and ibuprofen 97.5 mg.
The Mark Cuban Cost Plus Drug Company via their online marketplace.
AFT Pharmaceuticals has secured a new distribution channel for its non-opioid pain treatment, COMBOGESIC, through the Mark Cuban Cost Plus Drug Company marketplace. This strategic expansion aims to increase US market penetration for the acetaminophen and ibuprofen combination therapy, positioning the firm for potential revenue growth in the competitive pain management sector.
The partnership provides AFT with a direct-to-consumer distribution channel in the US for its non-opioid pain medication, COMBOGESIC, significantly increasing its market accessibility.